Hartford Investment Management Co. Lowers Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Hartford Investment Management Co. lessened its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.7% in the third quarter, Holdings Channel reports. The firm owned 6,686 shares of the biopharmaceutical company’s stock after selling 114 shares during the period. Hartford Investment Management Co.’s holdings in Regeneron Pharmaceuticals were worth $7,029,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently added to or reduced their stakes in the stock. Brown Lisle Cummings Inc. raised its stake in shares of Regeneron Pharmaceuticals by 18.2% during the 2nd quarter. Brown Lisle Cummings Inc. now owns 65 shares of the biopharmaceutical company’s stock valued at $68,000 after purchasing an additional 10 shares during the period. Sachetta LLC raised its position in Regeneron Pharmaceuticals by 71.4% in the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 10 shares during the period. Adirondack Trust Co. boosted its holdings in Regeneron Pharmaceuticals by 2.4% during the 3rd quarter. Adirondack Trust Co. now owns 431 shares of the biopharmaceutical company’s stock valued at $453,000 after acquiring an additional 10 shares during the period. UMB Bank n.a. grew its holdings in shares of Regeneron Pharmaceuticals by 1.1% in the third quarter. UMB Bank n.a. now owns 908 shares of the biopharmaceutical company’s stock worth $955,000 after purchasing an additional 10 shares during the last quarter. Finally, Team Hewins LLC increased its position in shares of Regeneron Pharmaceuticals by 2.5% in the first quarter. Team Hewins LLC now owns 451 shares of the biopharmaceutical company’s stock valued at $434,000 after acquiring an additional 11 shares during the period. Institutional investors own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

REGN has been the subject of a number of research reports. Piper Sandler increased their price objective on Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the stock an “overweight” rating in a report on Friday, August 23rd. Leerink Partners restated a “market perform” rating and issued a $1,077.00 price target (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $1,152.00 target price on shares of Regeneron Pharmaceuticals in a report on Thursday, June 27th. Barclays reduced their target price on shares of Regeneron Pharmaceuticals from $1,220.00 to $1,080.00 and set an “overweight” rating for the company in a report on Wednesday. Finally, Morgan Stanley decreased their price target on Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating on the stock in a report on Thursday, July 11th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, sixteen have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,102.19.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, VP Jason Pitofsky sold 487 shares of the company’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total value of $521,090.00. Following the sale, the vice president now owns 4,204 shares in the company, valued at $4,498,280. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, VP Jason Pitofsky sold 487 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the completion of the transaction, the vice president now owns 4,204 shares of the company’s stock, valued at $4,498,280. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 7.48% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock traded down $20.33 during trading hours on Wednesday, reaching $942.01. 41,565 shares of the company’s stock were exchanged, compared to its average volume of 500,459. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62. Regeneron Pharmaceuticals, Inc. has a 1 year low of $769.19 and a 1 year high of $1,211.20. The company has a market cap of $103.85 billion, a P/E ratio of 25.49, a price-to-earnings-growth ratio of 3.40 and a beta of 0.12. The company’s 50 day moving average is $1,102.60 and its two-hundred day moving average is $1,041.37.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, beating analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The company had revenue of $3.55 billion during the quarter, compared to the consensus estimate of $3.38 billion. During the same quarter last year, the company earned $8.79 earnings per share. Regeneron Pharmaceuticals’s quarterly revenue was up 12.3% compared to the same quarter last year. Equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.6 EPS for the current fiscal year.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.